Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Glatiramer promotes oligodendroglial cell maturation in a cuprizone-induced demyelination model.
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.
Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Sustained cortical and subcortical neuromodulation induced by electrical tongue stimulation.
Primary progressive multiple sclerosis-why we are failing.
The Oxford English Corpus: Facts about the language, The Story of Dictionaries
Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells.
Prevention and Mitigation of Experimental Autoimmune Encephalomyelitis by Murine β-Defensins via Induction of Regulatory T Cells.
Risk alleles for multiple sclerosis identified by a genomewide study.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
Population pharmacokinetics and pharmacodynamics of dalfampridine-ER in healthy volunteers and in patients with MS.
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
The complex role of estrogens in inflammation.
Safety Study of Combination Therapy with Intramuscular Avonex and Oral CellCept in Patients with Multiple Sclerosis
Differential effects of interferon-β1b on cytokine patterns of CD4+ and CD8+ T cells derived from RRMS and PPMS patients.
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.
Brain MRI results of DECIDE: a randomized, double-blind trial of DAC HYP vs. IFNβ-1a in RRMS patients
IFN-β Treatment Requires B Cells for Efficacy in Neuroautoimmunity.
Microglial/macrophage accumulation during cuprizone-induced demyelination in C57BL/6 mice.
A timing-of-birth effect on multiple sclerosis clinical phenotype.
Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis.
Phase III study: Ocrelizumab significantly reduces disease activity in PPMS patients
INF-β1b therapy modulates L-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis.
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Pages
« first
‹ previous
…
12
13
14
15
16
17
18
19
20
…
next ›
last »